Protective Effect of Silymarin and Gallic Acid against Cisplatin-Induced Nephrotoxicity and Hepatotoxicity


Creative Commons License

Doğan D., Meydan İ., Kömüroğlü A. U.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, SUPPLEMENT, vol.1, no.1, pp.1-10, 2022 (SCI-Expanded)

Abstract

Objective. 'is study aimed to investigate the effects of gallic acid and silymarin against nephrotoxicity and hepatotoxicity caused

by cisplatin. Materials and Methods. In the study, 56 Wistar Albino rats were equally divided into eight groups. Group 1 was the

control group; group 2 was the group receiving cisplatin; group 3 was the group receiving cisplatin + gallic acid; group 4 was the

group receiving cisplatin + silymarin; group 5 was the group receiving cisplatin + silymarin + gallic acid; group 6 was the group

receiving silymarin; group 7 was the group receiving gallic acid; group 8 was the group receiving gallic acid + silymarin. AST, ALT,

urea, creatinine, albumin, globulin, and total protein levels were measured at the end of the study. Superoxide dismutase (SOD),

catalase (CAT), malondialdehyde (MDA), glutathione (GSH), and 8-hydroxy-2′-deoxyguanosine (8OH-dG) levels were measured

in kidney and liver tissues. Additionally, histopathological evaluations of the tissues were also performed. Results. In kidney

and liver tissues, cisplatin significantly increasedMDAand 8-OHdG levels compared with treatment groups (p < 0.05). Silymarintreated

group significantly increased the SOD activity and GSH amount in the liver tissue compared with the cisplatin-treated

group (p < 0.05). Gallic acid significantly increased CAT activity compared with the cisplatin-treated group (p < 0.05). It was

determined that the cisplatin-treated group significantly decreased CAT and SOD activity compared with the control group

(p > 0.05). Gallic acid showed a significant increase in CATand SOD activity in kidney tissue compared with the cisplatin-treated

group (p < 0.05). Conclusion. As a result, it was observed that gallic acid silymarin had a protective effect on cisplatin-induced

nephrotoxic and hepatotoxic effects.